Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$32.68 USD
+0.11 (0.34%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $32.70 +0.02 (0.06%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
VKTX 32.68 +0.11(0.34%)
Will VKTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VKTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VKTX
NVO Stock Crashes 22% After 2025 View Cut: More Downside Ahead?
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
VKTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect
Can Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
Other News for VKTX
Novo Nordisk's Downgraded Expectations - What The Market Is (Obviously) Missing
Benzinga Bulls And Bears: T-Mobile, LendingTree, Molina Healthcare — And Trade Deal Optimism Boosts Markets
Benzinga Bulls And Bears: T-Mobile, LendingTree, Molina Healthcare — And Trade Deal Optimism Boosts Markets
Viking Therapeutics Q2: Confidently Continuing The Recovery
Viking Therapeutics Receives Buy Rating Amid Promising Clinical Developments and Strategic Initiatives